CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005–2009

Therese A Dolecek; Jennifer M Propp; Nancy E Stroup; Carol Kruchko

doi:10.1093/neuonc/nos218

. 2012 Nov;14(Suppl 5):v1–v49. doi: 10.1093/neuonc/nos218

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005–2009

Therese A Dolecek, Jennifer M Propp, Nancy E Stroup, Carol Kruchko

PMCID: PMC3480240 PMID: 23095881

Introduction

The objective of CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005–2009 is to provide a current and comprehensive review of the descriptive epidemiology of primary brain and central nervous system (CNS) tumors in the United States population. CBTRUS has obtained data on all primary brain and CNS tumors from the Centers for Disease Control and Prevention, National Program of Cancer Registries (NPCR) and the National Cancer Institute, Surveillance, Epidemiology and End Results (SEER) program for diagnosis years 2005–2009. Incidence counts and rates of primary malignant and non-malignant brain and CNS tumors are documented by histology, gender, age, race, and Hispanic ethnicity.

Background

The Central Brain Tumor Registry of the United States (CBTRUS) is a unique professional research organization that focuses exclusively on providing quality statistical data on population-based primary brain and CNS incident tumors in the United States. CBTRUS is currently the only population-based site-specific registry in the United States that works in partnership with a public surveillance organization, the National Program of Central Registries (NPCR), and from which data are directly received under a special agreement. This agreement permits transfer of data through the NPCR-CSS Submission Specifications mechanism,¹ the system utilized for collection of central (state) cancer data as mandated in 1992 by Public Law 102-515, the Cancer Registries Amendment Act.² CBTRUS combines the NPCR data with data from the SEER program³ which was established for national cancer surveillance in the early 1970s. Working with these premier surveillance organizations enables CBTRUS to report high quality data on brain and CNS tumors that are useful to the communities it serves.

Since 1995, CBTRUS has self-published fourteen reports that have contributed to the surveillance of brain and CNS tumors in the United States. As a result of partnering with the Society for Neuro-Oncology (SNO)⁴, this fifteenth CBTRUS report is the first to be published as a supplement to Neuro-Oncology, the official journal of SNO and marks an historic milestone for both organizations.

CBTRUS was incorporated as a nonprofit 501(c)3 organization with a founding and sustaining grant from the Pediatric Brain Tumor Foundation in 1992 following a two–year study conducted by the American Brain Tumor Association to determine the feasibility of a central registry for all primary brain and CNS tumor cases in the United States. Until that time, standard data reporting in the United States had been limited to only malignant cases. Non–malignant brain tumors, those classified as having a benign or uncertain behavior, however, may, and often do, impose similar costs to society in terms of medical care, case fatality, and lost productivity as do malignant brain tumors. In addition, as molecular markers have been discovered, it has become clear that certain non–malignant brain tumors may become malignant over time.

Passed in 2002, the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107–260)⁵ expanded the collection of primary brain and CNS tumor incidence data by the NPCR to include non-malignant brain and CNS tumors having International Classification of Diseases for Oncology Third Edition (ICD-O-3)⁶ codes beginning with the 2004 diagnosis year. All central (state) cancer registries now include these data in their collection practices. Starting in 2004, Uniform Data Standards (UDS) as directed by the North American Association of Cancer Registries (NAACCR)⁷, an umbrella organization for tumor registries, governmental agencies, professional associations and private groups, guide the collection of required information on non-malignant brain and CNS tumors; in 2005, the UDS for the collection of malignant brain and CNS tumors were revised. The Multiple Primary and Histology Coding Rules for malignant and non-malignant brain and CNS tumors have been undergoing revision in 2012 under the leadership of SEER.

The CBTRUS database contains the largest aggregation of population–based data on the incidence of all primary brain and CNS tumors in the United States. This report represents a dramatic increase in population coverage (approximately 97% from the initial CBTRUS Reports). The central cancer registries receive population-based, standardized data from all healthcare data sources primarily through certified tumor registrars. Along with the UDS, there are quality control checks and a system for rating each central registry to further insure that these data are reported as accurately and completely as possible. These individuals and organizations provide the high quality data that are the foundation of the CBTRUS statistical reports and scientific activities.

This statistical report continues the past efforts that CBTRUS has made to provide population–based incidence rates for all primary brain and CNS tumors by histology, age, gender, race, and Hispanic ethnicity. As in previous reports, these data have been organized by clinically relevant histological groupings that are useful for surveillance. The information is important for allocation and planning of specialty health–care services, in the planning of disease prevention and control programs, and in research activities. These data may lead to clues that will stimulate research into the causes of this terrible disease.

In 2012, the CBTRUS staff in collaboration with three neuropathologists, Drs. Janet Bruner (University of Texas M.D. Anderson Medical Center), Roger McLendon (Duke University) and Tarik Tihan (University of California at San Francisco) revised the CBTRUS Histology Grouping Scheme to reflect the 2007 WHO Classification of Tumours of the Central Nervous System.⁸ CBTRUS will continue to update its grouping scheme to reflect state-of-the-art classification for brain and CNS tumors mindful that any future revisions will incorporate accepted ICD-O coding. CBTRUS will continue to share its expertise and to work cooperatively with other surveillance organizations as well as brain tumor clinicians and researchers to assure that primary brain and CNS tumors are collected and reported as accurately and completely as possible.

Technical Notes

Data Collection

CBTRUS does not collect data directly from patient's medical records. As noted, data for CBTRUS analyses come from NPCR and SEER programs. By law, cancer and benign brain tumors are reportable diseases, and central cancer registries in states are mandated to collect pertinent information on their residents, collate these data, and provide data files to NPCR and SEER. State central cancer registries (including the District of Columbia) play an essential role in the collection process, diagrammatically presented as follows.

graphic file with name nos21820.jpg

CBTRUS obtained incidence data from 49 population-based cancer registries (44 NPCR and 5 SEER) that include cases of malignant and non–malignant (benign and uncertain) primary brain and CNS tumors. It should be noted that metastatic tumors including those found in the brain and CNS are not collected by surveillance organizations in the United States. Data were requested for all newly-diagnosed primary malignant and non-malignant tumors in 2005–2009 at any of the following anatomic sites (ICD-O-3 topography codes in parentheses): brain (C71.0–C71.9), meninges (C70.0–C70.9), spinal cord, cranial nerves, and other parts of the central nervous system (C72.0–C72.9), pituitary and pineal glands (C75.1–C75.3), and olfactory tumors of the nasal cavity [C30.0 (ICD-O-3 histology codes 9522 and 9523)].⁶

NPCR provided data on 300,205 primary brain and CNS tumors diagnosed in 2005–2009. NPCR cancer registries had to agree to participate in the CBTRUS Statistical Report and to pass certain data quality standards required by NPCR in order for CBTRUS to receive data. From the SEER research data files, data from state central cancer registries not included in the NPCR dataset were obtained and included 12,339 primary brain and CNS tumor case records diagnosed in 2005–2009. These data were combined into a single data set for analyses. A total of 1,342 records (0.43%) were deleted from the final analytic data set because of invalid site/histology combinations based on a review by the CBTRUS consulting neuropathologist, or because of reclassification based on adjudication of multiple records. Of these, 131 cases had bilateral acoustic neuromas in which the records were consolidated. The final analytic data set included 311,202 records from 49 population-based central cancer registries.

Definitions

Measures in Surveillance Epidemiology

The incidence rate is the basic measure of disease occurrence as it expresses probability or risk of disease in a defined population over a specified period of time. Incidence Rates measure the occurrence of newly-diagnosed cases of disease per 100,000 population. Mortality Rates quantify the number of people who have died from the disease per 100,000 population in a specific time period. Prevalence Rates measure the number of people with a disease per 100,000 population at a particular point in time or during a particular period of time. Survival Rates (percentages) are the probability of surviving for a specified time period. Relative Survival Rates are defined as the observed probability of survival adjusted for the expected survival rate of the population for that age, gender and calendar year.

Incidence and mortality rates in this report are expressed per units of observation. For cancer, rates are usually expressed per 100,000 population. The unadjusted rate of disease in an entire population is the Crude Rate. Crude rates are frequently adjusted by age because as a population ages the crude rate would increase, reflecting only the aging of the population, not an actual incidence increase. Age–Adjusted Rates to a common standard population allow for comparisons of rates in populations across regions with different age structures. Incidence and mortality brain and CNS tumor rates in this report are age adjusted to the Year 2000 U.S. Standard Population. Rates for a subset of a population are termed specific rates. Age–Specific Rates that describe the rate of disease in a defined age group are presented in this report. Specific rates by gender, race, and Hispanic ethnicity are also reported. The variability around the estimates of rates is reflected in the Standard Error, which is incorporated into the formula for computing the confidence interval associated with a certain rate. A Confidence Interval (CI) is the computed interval with a given probability, eg, 95 percent, that the true value of a variable such as a mean, proportion or rate occurs within the interval. For example, the age–adjusted primary brain and CNS tumor incidence rate is 20.59 cases per 100,000. We can assume with 95 percent certainty that the actual incidence rate is within the range of 20.52 and 20.66 cases per 100,000. Statistically Significant refers to the likelihood that a result or relationship is caused by something other than mere random chance. Statistical hypothesis testing is traditionally employed to determine if a result is statistically significant or not. This provides a “p-value” representing the probability that random chance could explain the result. In general, a 5% or lower p-value is considered to be statistically significant.

In order to be able to compare incidence rates among statistical reports, agencies, or registries a number of factors should be considered such as whether the case definition, data collection, and rate calculation are similar by asking some of the following questions:

How is an incident case defined?
Are all primary malignant and non–malignant tumors included in the data set?
Or, are only malignant tumors being analyzed?
What anatomic locations (primary sites) are included?
Are lymphomas and hematopoietic neoplasms included in the incidence rates?
Are the populations comparable?
Are the incidence rates age–adjusted? And if so, to which standard population are they age–adjusted?

Classification by Behavior and Histology

Brain and CNS tumor classifications according to behavior ICD-O-3 standards for benign, uncertain and malignant behaviors are coded 0, 1, and 3, respectively. The histology groupings in CBTRUS statistical reports were initially developed in collaboration with the CBTRUS consulting neuropathologist, Dr. Janet Bruner. In 2012, Drs. Roger McLendon and Tarik Tihan joined Dr. Bruner and the CBTRUS staff to synchronize the CBTRUS histology grouping scheme with the 2007 World Health Organization (WHO) classification of tumors of the central nervous system.^8,9 This report uses this most recent 2012 CBTRUS histology grouping scheme (Table 1). The classification scheme utilizes ICD-O-3 codes⁶ and may include morphology codes that were not previously reported to CBTRUS.¹⁰ Tables 1a and 1b list malignant only and non-malignant only histologies, respectively. In this report, incidence rates are provided by major histology grouping and detailed histology.

Table 1.

Central Brain Tumor Registry of the United States (CBTRUS), Brain and Central Nervous System Tumor Histology Groupings

Histology	ICD-O-3^† Histology Code
Tumors of Neuroepithelial Tissue
Pilocytic astrocytoma	9421
Diffuse astrocytoma	9400, 9410, 9411, 9420
Anaplastic astrocytoma	9401
Unique astrocytoma variants	9381, 9384, 9424
Glioblastoma	9440, 9441, 9442/3^‡
Oligodendroglioma	9450
Anaplastic oligodendroglioma	9451, 9460
Oligoastrocytic tumors	9382
Ependymal tumors	9383, 9391, 9392, 9393, 9394
Glioma malignant, NOS	9380
Choroid plexus tumors	9390
Other neuroepithelial tumors	9363, 9423, 9430, 9444
Neuronal and mixed neuronal-glial tumors	8680, 8681, 8690, 8693, 9412, 9413, 9442/1^§,
	9492 (excluding site C75.1), 9493, 9505, 9506, 9522, 9523
Tumors of the pineal region	9360, 9361, 9362
Embryonal tumors	8963, 9364, 9470, 9471, 9472, 9473, 9474,
	9490, 9500, 9501, 9502, 9508
Tumors of Cranial and Spinal Nerves
Nerve sheath tumors	9540, 9541, 9550, 9560, 9561, 9570, 9571
Other tumors of cranial and spinal nerves	9562
Tumors of Meninges
Meningioma	9530, 9531, 9532, 9533, 9534, 9537, 9538, 9539
Mesenchymal tumors	8324, 8800, 8801, 8802, 8803, 8804, 8805, 8806, 8810, 8815, 8824, 8830,
	8831, 8835, 8836, 8850, 8851, 8852, 8853, 8854, 8857, 8861, 8870, 8880,
	8890, 8897, 8900, 8901, 8902, 8910, 8912, 8920, 8921, 8935, 8990, 9040, 9136,
	9150, 9170, 9180, 9210, 9241, 9260, 9373, 9480
Primary melanocytic lesions	8720, 8728, 8770, 8771
Other neoplasms related to the meninges	9161, 9220, 9231, 9240, 9243, 9370, 9371, 9372, 9535
Lymphomas and Hemopoietic Neoplasms
Lymphoma	9590, 9591, 9596, 9650, 9651, 9652, 9653, 9654, 9655, 9659, 9661,
	9662, 9663, 9664, 9665, 9667, 9670, 9671, 9673, 9675, 9680, 9684,
	9687, 9690, 9691, 9695, 9698, 9699, 9701, 9702, 9705, 9714, 9719,
	9728, 9729
Other hemopoietic neoplasms	9727, 9731, 9733, 9734, 9740, 9741, 9750, 9751, 9752, 9753, 9754, 9755,
	9756, 9757, 9758, 9760, 9766, 9823, 9826, 9827, 9832, 9837, 9860, 9861, 9866, 9930, 9970
Germ Cell Tumors and Cysts
Germ cell tumors, cysts and heterotopias	8020, 8440, 9060, 9061, 9064, 9065, 9070, 9071, 9072, 9080, 9081, 9082,
	9083, 9084, 9085, 9100, 9101
Tumors of Sellar Region
Tumors of the pituitary	8040, 8140, 8146, 8246, 8260, 8270, 8271, 8272,
	8280, 8281, 8290, 8300, 8310, 8323, 9492 (Site C75.1 only), 9582
Craniopharyngioma	9350, 9351, 9352
Unclassified Tumors
Hemangioma	9120, 9121, 9122, 9123, 9125, 9130, 9131, 9133, 9140
Neoplasm, unspecified	8000, 8001, 8002, 8003, 8004, 8005, 8010, 8021
All other	8320, 8452, 8710, 8711, 8713, 8811, 8840, 8896, 8980, 9173, 9503, 9580

Histology	ICD-O-3^‡ Histology Code
Tumors of Neuroepithelial Tissue
Pilocytic astrocytoma	9421/1 [Included with malignant tumors]
Diffuse astrocytoma	9400/3, 9410/3, 9411/3, 9420/3
Anaplastic astrocytoma	9401/3
Unique astrocytoma variants	9381/3, 9424/3
Glioblastoma	9440/3, 9441/3, 9442/3
Oligodendroglioma	9450/3
Anaplastic oligodendroglioma	9451/3, 9460/3
Oligoastrocytic tumors	9382/3
Ependymal tumors	9391/3, 9392/3, 9393/3
Glioma malignant, NOS	9380/3
Choroid plexus	9390/3
Other neuroepithelial tumors	9423/3, 9430/3
Neuronal and mixed neuronal- glial tumors	8680/3, 8693/3, 9505/3, 9522/3, 9523/3
Tumors of the pineal region	9362/3
Embryonal tumors	8963/3, 9364/3, 9470/3, 9471/3, 9472/3,9473/3, 9474/3,
	9490/3, 9500/3, 9501/3, 9502/3, 9508/3
Tumors of Cranial and Spinal Nerves
Nerve sheath tumors	9540/3, 9560/3, 9561/3, 9571/3
Tumors of Meninges
Meningioma	9530/3, 9538/3, 9539/3
Mesenchymal tumors	8800/3, 8801/3, 8802/3, 8803/3, 8804/3, 8805/3, 8806/3, 8810/3, 8815/3, 8830/3,
	8850/3, 8851/3, 8852/3, 8853/3, 8854/3, 8857/3, 8890/3, 8900/3, 8901/3, 8902/3,
	8910/3, 8912/3, 8920/3, 8921/3, 8990/3, 9040/3, 9150/3, 9170/3, 9180/3, 9260/3, 9480/3
Primary melanocytic lesions	8720/3, 8728/3, 8770/3, 8771/3
Other neoplasms related to the meninges	9220/3, 9231/3, 9240/3, 9243/3, 9370/3, 9371/3, 9372/3
Lymphomas and Hemopoietic Neoplasms
Lymphoma	9590/3, 9591/3, 9596/3, 9650/3, 9651/3, 9652/3, 9653/3, 9654/3, 9655/3, 9659/3,
	9661/3, 9662/3, 9663/3, 9664/3, 9665/3, 9667/3, 9670/3, 9671/3, 9673/3, 9675/3,
	9680/3, 9684/3, 9687/3, 9690/3, 9691/3, 9695/3, 9698/3, 9699/3, 9701/3, 9702/3,
	9705/3, 9714/3, 9719/3, 9728/3, 9729/3
Other hemopoietic neoplasms	9727/3, 9731/3, 9733/3, 9734/3, 9740/3, 9741/3, 9750/3, 9754/3, 9755/3, 9756/3, 9757/3, 9758/3,
	9760/3, 9823/3, 9826/3, 9827/3, 9832/3, 9837/3, 9860/3, 9861/3, 9866/3, 9930/3
Germ Cell Tumors and Cysts
Germ cell tumors, cysts and	8020/3, 8440/3, 9060/3, 9061/3, 9064/3, 9065/3, 9070/3, 9071/3, 9072/3, 9080/3,
heterotopias	9081/3, 9082/3, 9083/3, 9084/3, 9085/3, 9100/3, 9101/3
Tumors of Sellar Region
Tumors of the pituitary	8140/3, 8246/3, 8260/3, 8270/3, 8272/3, 8280/3, 8281/3, 8290/3, 8300/3, 8310/3, 8323/3
Unclassified Tumors
Hemangioma	9120/3, 9130/3, 9133/3, 9140/3
Neoplasm, unspecified	8000/3, 8001/3, 8002/3, 8003/3, 8004/3, 8005/3, 8010/3, 8021/3
All other	8320/3, 8710/3, 8711/3, 8811/3, 8840/3, 8896/3, 8980/3, 9503/3, 9580/3

	Total	Gender		Race				Hispanic Ethnicity^†
Histology		Male	Female	White	Black	AIAN	API	Hispanic	Non-Hispanic
Tumors of Neuroepithelial Tissue	99,063	55,149	43,914	88,414	6,666	516	1,823	9,034	90,029
Pilocytic astrocytoma	4,636	2,374	2,262	3,870	491	39	104	649	3,987
Diffuse astrocytoma	8,616	4,811	3,805	7,616	591	67	170	814	7,802
Anaplastic astrocytoma	5,374	3,059	2,315	4,856	295	31	103	455	4,919
Unique astrocytoma variants	938	500	438	757	126	–	–	132	806
Glioblastoma	49,088	27,994	21,094	45,140	2,614	182	668	3,203	45,885
Oligodendroglioma	3,973	2,181	1,792	3,558	231	19	85	419	3,554
Anaplastic oligodendroglioma	1,687	933	754	1,507	88	–	40	156	1,531
Oligoastrocytic tumors	3,020	1,724	1,296	2,691	165	22	81	310	2,710
Ependymal tumors	6,117	3,371	2,746	5,311	473	41	144	707	5,410
Glioma malignant, NOS	6,574	3,329	3,245	5,569	638	33	164	770	5,804
Choroid plexus tumors	772	375	397	664	58	–	21	131	641
Other neuroepithelial tumors	95	35	60	80	–	–	–	–	82
Neuronal and mixed neuronal-glial tumors	3,887	2,093	1,794	3,245	396	25	108	438	3,449
Tumors of the pineal region	579	240	339	444	103	–	–	80	499
Embryonal tumors	3,707	2,130	1,577	3,106	384	24	111	757	2,950
Tumors of Cranial and Spinal Nerves	25,942	12,377	13,565	22,614	1,349	106	854	2,108	23,834
Nerve sheath tumors	25,926	12,371	13,555	22,603	1,348	106	852	2,107	23,819
Other tumors of cranial and spinal nerves	16	–	–	–	–	–	–	–	–
Tumors of Meninges	114,363	31,030	83,333	94,854	13,112	592	3,380	9,790	104,573
Meningioma	110,359	28,884	81,475	91,469	12,757	561	3,238	9,298	101,061
Mesenchymal tumors	1,192	584	608	998	113	–	38	127	1,065
Primary melanocytic lesions	106	65	41	95	–	–	–	–	91
Other neoplasms related to the meninges	2,706	1,497	1,209	2,292	236	19	101	350	2,356
Lymphomas and Hemopoietic Neoplasms	6,956	3,701	3,255	5,874	693	39	251	721	6,235
Lymphoma	6,774	3,607	3,167	5,731	667	36	245	694	6,080
Other hemopoietic neoplasms	182	94	88	143	26	–	–	27	155
Germ Cell Tumors and Cysts	1,418	967	451	1,126	146	–	91	285	1,133
Germ cell tumors, cysts and heterotopias	1,418	967	451	1,126	146	–	91	285	1,133
Tumors of Sellar Region	46,562	21,057	25,505	34,608	8,535	372	1,566	6,699	39,863
Tumors of the pituitary	43,882	19,728	24,154	32,590	8,056	351	1,473	6,289	37,593
Craniopharyngioma	2,680	1,329	1,351	2,018	479	21	93	410	2,270
Unclassified Tumors	16,898	7,489	9,409	14,313	1,733	108	337	1,791	15,107
Hemangioma	3,240	1,436	1,804	2,765	256	17	111	370	2,870
Neoplasm, unspecified	13,566	6,008	7,558	11,471	1,470	89	222	1,409	12,157
All other	92	45	47	77	–	–	–	–	80
Total	311,202	131,770	179,432	261,803	32,234	1,742	8,302	30,428	280,774

	Age at Diagnosis
Histology	0-4	5-9	10-14	15-19	0-19	0-14
Tumors of Neuroepithelial Tissue	4,566	3,596	3,136	2,854	14,152	11,298
Pilocytic astrocytoma	886	867	849	618	3,220	2,602
Diffuse astrocytoma	334	217	259	272	1,082	810
Anaplastic astrocytoma	53	80	91	96	320	224
Unique astrocytoma variants	65	94	134	137	430	293
Glioblastoma	89	139	160	174	562	388
Oligodendroglioma	30	36	57	110	233	123
Anaplastic oligodendroglioma	–	–	–	25	49	24
Oligoastrocytic tumors	28	25	32	52	137	85
Ependymal tumors	402	226	211	273	1,112	839
Glioma malignant, NOS	875	789	427	254	2,345	2,091
Choroid plexus tumors	265	40	38	51	394	343
Other neuroepithelial tumors	–	–	–	–	30	23
Neuronal and mixed neuronal-glial tumors	248	297	429	482	1,456	974
Tumors of the pineal region	53	38	32	42	165	123
Embryonal tumors	1,232	737	387	261	2,617	2,356
Tumors of Cranial and Spinal Nerves	272	207	252	369	1,100	731
Nerve sheath tumors	272	207	252	369	1,100	731
Other tumors of cranial and spinal nerves	–	–	–	–	–	–
Tumors of Meninges	139	98	210	410	857	447
Meningioma	70	60	143	275	548	273
Mesenchymal tumors	56	28	31	35	150	115
Primary melanocytic lesions	–	–	–	–	19	–
Other neoplasms related to the meninges	–	–	33	94	140	46
Lymphomas and Hemopoietic Neoplasms	–	22	20	35	90	55
Lymphoma	–	–	–	25	59	34
Other hemopoietic neoplasms	–	–	–	–	31	21
Germ Cell Tumors and Cysts	129	133	262	299	823	524
Germ cell tumors, cysts and heterotopias	129	133	262	299	823	524
Tumors of Sellar Region	174	358	608	1,520	2,660	1,140
Tumors of the pituitary	33	107	392	1,362	1,894	532
Craniopharyngioma	141	251	216	158	766	608
Unclassified Tumors	224	175	252	376	1,027	651
Hemangioma	49	38	74	132	293	161
Neoplasm, unspecified	173	136	176	242	727	485
All other	–	–	–	–	–	–
Total	5,517	4,589	4,740	5,863	20,709	14,846

State	No. of Newly Diagnosed Tumors	Percent Non-Malignant Tumors	Histologically Confirmed Percent	Radio-graphically Confirmed Percent	Average Annual 2005–2009 Population^†
Alabama	4,170	57.4	71.7	24.6	4,632,619
Alaska	669	68.5	62.0	34.8	683,142
Arizona	6,343	63.9	64.8	29.2	6,324,866
Arkansas	2,954	63.6	58.8	35.1	2,838,145
California	33,666	64.8	69.0	27.6	36,308,524
Colorado	6,123	71.8	53.7	43.5	4,843,209
Connecticut	3,499	58.1	73.1	24.0	3,494,486
Delaware	898	59.8	71.0	25.3	863,831
District of Columbia	485	56.9	67.0	27.4	588,433
Florida	23,552	68.3	58.2	38.2	18,222,422
Georgia	8,805	65.0	63.7	32.6	9,497,665
Hawaii	1,264	73.4	60.8	36.1	1,280,241
Idaho	1,438	58.2	68.8	26.4	1,492,565
Illinois	13,649	66.3	60.1	37.5	12,785,049
Indiana	6,500	62.2	58.2	39.0	6,342,471
Iowa	3,363	60.8	63.3	34.1	2,978,881
Kentucky	5,629	69.5	52.9	43.3	4,251,998
Louisiana	4,271	66.7	65.1	31.2	4,383,629
Maine	1,291	52.9	76.8	19.1	1,316,379
Massachusetts	6,426	58.2	74.4	21.7	6,511,177
Michigan	11,158	64.0	62.4	33.2	10,039,210
Minnesota	4,210	56.7	96.8	0.0	5,188,579
Mississippi	2,754	64.4	63.4	31.8	2,916,885
Missouri	6,727	65.3	61.3	34.4	5,904,390
Montana	1,022	62.2	69.2	26.5	956,256
Nebraska	1,729	59.1	70.9	25.9	1,772,127
Nevada	2,117	60.8	71.7	22.5	2,545,764
New Hampshire	1,385	59.9	72.1	25.2	1,315,420
New Jersey	9,001	60.9	68.4	27.1	8,650,548
New Mexico	1,659	61.5	71.5	20.9	1,964,862
New York	23,773	68.4	61.3	35.4	19,423,895
North Carolina	9,568	65.2	69.9	27.0	9,045,704
North Dakota	554	55.6	60.3	33.9	639,721
Ohio	10,658	56.2	70.4	24.4	11,511,858
Oklahoma	3,286	56.6	64.6	31.6	3,610,073
Oregon	4,031	60.7	72.3	25.7	3,727,404
Pennsylvania	15,836	65.8	61.8	32.8	12,516,594
Rhode Island	1,149	64.6	68.9	27.9	1,057,381
South Carolina	4,524	63.4	63.1	30.9	4,416,870
South Dakota	714	60.8	65.7	30.7	796,511
Tennessee	7,026	66.0	60.4	36.4	6,158,955
Texas	25,611	68.8	56.5	37.2	23,818,417
Utah	2,517	66.0	74.3	24.9	2,651,814
Vermont	899	65.3	63.1	34.5	620,414
Virginia	7,064	63.1	69.9	27.0	7,721,729
Washington	8,530	69.9	56.7	39.8	6,465,754
West Virginia	2,063	61.0	61.3	35.8	1,811,401
Wisconsin	6,143	60.8	92.8	4.2	5,599,416
Wyoming	499	62.7	72.1	27.3	523,950
Total	311,202	64.8	64.6	31.5	293,011,631

	0-19 Years				20+ Years				All Ages
State	Malignant		Non-Malignant		Malignant		Non-Malignant		Malignant		Non-Malignant		All Tumors
	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI
Alabama	2.99	(2.57-3.45)	0.99	(0.76–1.26)	8.95	(8.51–9.40)	13.24	(12.70–13.79)	7.24	(6.90–7.58)	9.72	(9.34–10.13)	16.96	(16.45–17.49)
Alaska	2.77	(1.84–4.00)	3.61	(2.56–4.96)	8.98	(7.63–10.50)	19.96	(17.97–22.12)	7.20	(6.19–8.32)	15.27	(13.82–16.84)	22.47	(20.69–24.37)
Arizona	3.23	(2.87–3.62)	1.59	(1.34–1.87)	8.67	(8.29–9.06)	17.10	(16.57–17.65)	7.11	(6.82–7.41)	12.65	(12.26–13.05)	19.76	(19.28–20.26)
Arkansas	3.42	(2.87–4.06)	3.51	(2.95–4.14)	8.63	(8.08–9.20)	16.18	(15.42–16.97)	7.13	(6.71–7.58)	12.55	(11.98–13.13)	19.68	(18.97–20.41)
California	2.95	(2.80–3.10)	1.74	(1.63–1.86)	8.29	(8.13–8.46)	16.79	(16.56–17.02)	6.76	(6.64–6.88)	12.47	(12.30–12.64)	19.23	(19.02–19.44)
Colorado	2.78	(2.40–3.21)	1.83	(1.51–2.18)	9.21	(8.75–9.69)	25.94	(25.15–26.74)	7.37	(7.02–7.73)	19.02	(18.45–19.60)	26.39	(25.72–27.07)
Connecticut	3.33	(2.82–3.90)	1.54	(1.21–1.94)	9.68	(9.16–10.23)	14.41	(13.77–15.07)	7.86	(7.46–8.28)	10.72	(10.25–11.20)	18.58	(17.96–19.21)
Delaware	3.25	(2.29–4.48)	2.09	(1.34–3.11)	9.72	(8.68–10.85)	15.28	(13.98–16.68)	7.86	(7.07–8.73)	11.50	(10.54–12.52)	19.36	(18.10–20.68)
District of Columbia	2.73	(1.61–4.32)	–	–	8.82	(7.60–10.18)	12.01	(10.58–13.57)	7.08	(6.13–8.12)	9.18	(8.11–10.34)	16.25	(14.82–17.79)
Florida	3.40	(3.16–3.65)	1.94	(1.76–2.13)	8.77	(8.56–8.99)	20.29	(19.97–20.62)	7.23	(7.06–7.40)	15.03	(14.79–15.27)	22.26	(21.97–22.55)
Georgia	3.04	(2.75–3.34)	1.59	(1.39–1.81)	8.44	(8.12–8.77)	17.41	(16.95–17.89)	6.89	(6.64–7.14)	12.87	(12.54–13.22)	19.76	(19.34–20.18)
Hawaii	2.85	(2.08–3.80)	1.48	(0.95–2.20)	5.80	(5.14–6.52)	18.27	(17.08–19.51)	4.95	(4.43–5.52)	13.45	(12.59–14.36)	18.40	(17.39–19.46)
Idaho	2.86	(2.21–3.64)	1.42	(0.97–2.01)	10.26	(9.40–11.18)	15.56	(14.49–16.68)	8.14	(7.49–8.82)	11.50	(10.73–12.32)	19.64	(18.63–20.69)
Illinois	2.98	(2.73–3.24)	1.83	(1.64–2.04)	8.80	(8.53–9.08)	18.87	(18.47–19.27)	7.13	(6.93–7.34)	13.98	(13.69–14.27)	21.11	(20.76–21.47)
Indiana	3.58	(3.19–3.99)	1.85	(1.57–2.15)	9.09	(8.70–9.48)	16.62	(16.10–17.15)	7.51	(7.21–7.81)	12.38	(12.00–12.77)	19.89	(19.40–20.38)
Iowa	3.30	(2.76–3.91)	1.57	(1.21–2.00)	10.11	(9.53–10.71)	16.90	(16.15–17.67)	8.16	(7.72–8.62)	12.50	(11.95–13.06)	20.66	(19.95–21.38)
Kentucky	3.43	(2.96–3.95)	2.33	(1.95–2.77)	9.46	(8.99–9.96)	23.68	(22.93–24.46)	7.73	(7.37–8.11)	17.56	(17.01–18.12)	25.29	(24.63–25.97)
Louisiana	2.97	(2.56–3.44)	1.68	(1.37–2.03)	7.78	(7.35–8.23)	17.32	(16.67–17.98)	6.40	(6.07–6.75)	12.83	(12.36–13.32)	19.23	(18.65–19.82)
Maine	3.80	(2.89–4.91)	1.39	(0.87–2.12)	9.85	(9.03–10.73)	12.31	(11.37–13.31)	8.11	(7.47–8.80)	9.18	(8.49–9.91)	17.29	(16.34–18.28)
Massachusetts	3.42	(3.03–3.85)	1.61	(1.35–1.90)	9.51	(9.13–9.91)	14.18	(13.72–14.66)	7.77	(7.47–8.07)	10.57	(10.24–10.92)	18.34	(17.89–18.80)
Michigan	3.48	(3.17–3.81)	1.90	(1.68–2.15)	9.34	(9.03–9.66)	18.17	(17.74–18.61)	7.66	(7.42–7.90)	13.50	(13.19–13.82)	21.16	(20.76–21.56)
Minnesota	2.98	(2.59–3.42)	1.34	(1.09–1.64)	8.45	(8.03–8.87)	11.94	(11.45–12.44)	6.88	(6.56–7.21)	8.90	(8.54–9.27)	15.78	(15.30–16.27)
Mississippi	2.80	(2.32–3.35)	1.58	(1.23–2.00)	8.16	(7.62–8.73)	16.28	(15.51–17.08)	6.62	(6.21–7.05)	12.06	(11.51–12.64)	18.68	(17.99–19.40)
Missouri	3.20	(2.82–3.62)	1.50	(1.25–1.80)	9.19	(8.80–9.60)	19.05	(18.48–19.64)	7.47	(7.17–7.78)	14.02	(13.60–14.44)	21.49	(20.97–22.01)
Montana	2.36	(1.58–3.40)	1.74	(1.10–2.62)	9.28	(8.32–10.32)	16.44	(15.13–17.83)	7.30	(6.57–8.08)	12.22	(11.27–13.23)	19.52	(18.31–20.78)
Nebraska	3.58	(2.88–4.39)	2.58	(1.99–3.29)	9.49	(8.75–10.28)	14.58	(13.66–15.55)	7.80	(7.23–8.40)	11.14	(10.46–11.85)	18.94	(18.05–19.86)
Nevada	2.40	(1.91–2.96)	0.63	(0.39–0.95)	8.17	(7.58–8.78)	14.27	(13.49–15.10)	6.51	(6.07–6.98)	10.36	(9.79–10.95)	16.87	(16.15–17.61)
New Hampshire	3.71	(2.84–4.77)	2.26	(1.61–3.08)	9.70	(8.85–10.61)	15.30	(14.24–16.42)	7.98	(7.32–8.68)	11.56	(10.78–12.39)	19.54	(18.51–20.61)
New Jersey	3.63	(3.29–4.00)	1.88	(1.63–2.15)	9.40	(9.07–9.74)	15.85	(15.42–16.29)	7.75	(7.49–8.01)	11.84	(11.53–12.16)	19.59	(19.18–20.00)
New Mexico	2.17	(1.66–2.78)	1.70	(1.25–2.26)	7.99	(7.34–8.68)	13.57	(12.72–14.46)	6.32	(5.83–6.83)	10.17	(9.55–10.81)	16.48	(15.69–17.30)
New York	3.57	(3.34–3.81)	2.37	(2.19–2.57)	8.93	(8.71–9.15)	21.07	(20.74–21.41)	7.39	(7.23–7.56)	15.71	(15.46–15.95)	23.10	(22.80–23.40)
North Carolina	3.20	(2.89–3.53)	1.91	(1.68–2.17)	8.78	(8.46–9.10)	18.03	(17.57–18.50)	7.18	(6.93–7.42)	13.41	(13.07–13.75)	20.58	(20.17–21.00)
North Dakota	2.96	(1.89–4.40)	–	–	8.90	(7.74–10.18)	12.05	(10.69–13.54)	7.19	(6.30–8.18)	8.95	(7.95–10.03)	16.14	(14.79–17.58)
Ohio	3.41	(3.12–3.72)	2.01	(1.79–2.24)	9.32	(9.03–9.61)	12.84	(12.51–13.18)	7.62	(7.40–7.85)	9.73	(9.49–9.99)	17.36	(17.03–17.69)
Oklahoma	2.92	(2.47–3.44)	1.42	(1.11–1.79)	9.44	(8.92–9.98)	13.32	(12.70–13.95)	7.57	(7.18–7.98)	9.90	(9.45–10.37)	17.47	(16.87–18.09)
Oregon	3.77	(3.24–4.36)	2.39	(1.98–2.87)	9.75	(9.24–10.28)	16.15	(15.49–16.83)	8.03	(7.64–8.44)	12.20	(11.72–12.71)	20.24	(19.61–20.88)
Pennsylvania	3.52	(3.23–3.83)	1.98	(1.77–2.21)	9.46	(9.19–9.73)	19.73	(19.34–20.12)	7.76	(7.55–7.97)	14.63	(14.35–14.92)	22.39	(22.04–22.75)
Rhode Island	3.11	(2.23–4.23)	1.87	(1.22–2.75)	8.73	(7.85–9.69)	17.23	(15.98–18.56)	7.12	(6.44–7.86)	12.83	(11.91–13.80)	19.95	(18.80–21.15)
South Carolina	3.11	(2.67–3.59)	1.63	(1.32–1.98)	8.71	(8.27–9.17)	16.71	(16.08–17.35)	7.10	(6.76–7.46)	12.38	(11.93–12.85)	19.48	(18.91–20.07)
South Dakota	2.60	(1.74–3.74)	–	–	8.28	(7.27–9.39)	13.89	(12.58–15.30)	6.65	(5.88–7.49)	10.22	(9.26–11.24)	16.87	(15.64–18.17)
Tennessee	3.52	(3.13–3.95)	2.24	(1.93–2.59)	8.95	(8.57–9.34)	19.18	(18.62–19.76)	7.39	(7.10–7.70)	14.32	(13.91–14.74)	21.71	(21.20–22.23)
Texas	3.41	(3.22–3.60)	2.28	(2.13–2.44)	8.66	(8.46–8.87)	21.80	(21.47–22.14)	7.16	(7.00–7.32)	16.20	(15.96–16.45)	23.36	(23.07–23.65)
Utah	4.09	(3.53–4.72)	1.76	(1.39–2.19)	8.45	(7.81–9.13)	20.48	(19.47–21.53)	7.20	(6.71–7.71)	15.11	(14.38–15.86)	22.31	(21.43–23.21)
Vermont	2.20	(1.29–3.51)	2.54	(1.56–3.92)	11.70	(10.38–13.14)	22.99	(21.10–25.01)	8.97	(7.99–10.05)	17.13	(15.74–18.60)	26.10	(24.39–27.90)
Virginia	2.97	(2.65–3.33)	1.19	(0.99–1.42)	8.13	(7.80–8.48)	15.41	(14.95–15.88)	6.65	(6.40–6.92)	11.33	(10.99–11.67)	17.98	(17.56–18.41)
Washington	3.65	(3.26–4.08)	2.76	(2.42–3.14)	9.44	(9.05–9.85)	24.18	(23.55–24.82)	7.78	(7.48–8.09)	18.04	(17.58–18.51)	25.82	(25.27–26.38)
West Virginia	3.06	(2.36–3.89)	1.45	(0.99–2.05)	9.67	(8.98–10.41)	16.18	(15.27–17.13)	7.78	(7.24–8.35)	11.95	(11.29–12.65)	19.73	(18.87–20.62)
Wisconsin	3.67	(3.24–4.13)	1.64	(1.36–1.95)	10.02	(9.60–10.46)	16.99	(16.43–17.56)	8.20	(7.87–8.54)	12.59	(12.18–13.00)	20.78	(20.26–21.32)
Wyoming	2.39	(1.39–3.82)	–	–	8.79	(7.49–10.25)	15.23	(13.52–17.09)	6.95	(5.97–8.05)	11.37	(10.12–12.72)	18.32	(16.72–20.03)

ICD-O-3 Code	Site	Total			Male			Female
		N	Adjusted Rate	95% CI	N	Adjusted Rate	95% CI	N	Adjusted Rate	95% CI
C71.1-C71.4	Frontal, temporal, parietal, & occipital lobes of the brain	65,532	4.33	(4.29–4.36)	36,171	5.13	(5.08–5.18)	29,361	3.65	(3.60–3.69)
C71.0	Cerebrum	6,007	0.40	(0.39–0.41)	3,148	0.45	(0.43–0.46)	2,859	0.37	(0.35–0.38)
C71.5	Ventricle	3,639	0.25	(0.24–0.26)	1,993	0.28	(0.26–0.29)	1,646	0.22	(0.21–0.24)
C71.6	Cerebellum	8,601	0.59	(0.58–0.60)	4,655	0.65	(0.63–0.67)	3,946	0.53	(0.52–0.55)
C71.7	Brain stem	4,924	0.34	(0.33–0.35)	2,606	0.36	(0.35–0.38)	2,318	0.32	(0.31–0.33)
C71.8–C71.9	Other brain	30,334	2.00	(1.98–2.03)	15,763	2.28	(2.25–2.32)	14,571	1.77	(1.74–1.80)
C72.0–C72.1	Spinal cord and cauda equina	9,538	0.64	(0.63–0.65)	4,867	0.67	(0.65–0.69)	4,671	0.61	(0.59–0.62)
C72.2–C72.5	Cranial nerves	21,489	1.41	(1.39–1.43)	10,055	1.38	(1.35–1.41)	11,434	1.44	(1.42–1.47)
C72.8–C72.9	Other nervous system	1,902	0.13	(0.12–0.13)	1,013	0.14	(0.13–0.15)	889	0.11	(0.11–0.12)
C70.0–C70.9	Meninges (cerebral & spinal)	109,660	7.18	(7.14–7.22)	28,856	4.27	(4.22–4.32)	80,804	9.68	(9.61–9.75)
C75.1–C75.2	Pituitary	47,614	3.19	(3.16–3.22)	21,473	3.02	(2.98–3.06)	26,141	3.45	(3.40–3.49)
C75.3	Pineal	1,391	0.10	(0.09–0.10)	831	0.11	(0.11–0.12)	560	0.08	(0.07–0.08)
C30.0 (9522–9523)	Olfactory tumors of the nasal cavity	571	0.04	(0.03–0.04)	339	0.05	(0.04–0.05)	232	0.03	(0.03–0.03)
Total		311,202	20.59	(20.52–20.66)	131,770	18.80	(18.69–18.90)	179,432	22.25	(22.15–22.35)

	Total					Malignant			Non-malignant
Histology	N	% of All Tumors	Median Age	Rate	(95% CI)	N	Rate	(95% CI)	N	Rate	(95% CI)
Tumors of Neuroepithelial Tissue	99,063	31.8	55	6.60	(6.56–6.64)	92,418	6.14	(6.10–6.18)	6,645	0.46	(0.45–0.47)
Pilocytic astrocytoma	4,636	1.5	13	0.33	(0.32–0.34)	4,636	0.33	(0.32–0.34)	–	–	–
Diffuse astrocytoma	8,616	2.8	48	0.58	(0.57–0.60)	8,616	0.58	(0.57–0.60)	–	–	–
Anaplastic astrocytoma	5,374	1.7	54	0.36	(0.35–0.37)	5,374	0.36	(0.35–0.37)	–	–	–
Unique astrocytoma variants	938	0.3	22	0.07	(0.06–0.07)	613	0.04	(0.04–0.05)	325	0.02	(0.02–0.03)
Glioblastoma	49,088	15.8	64	3.19	(3.16–3.22)	49,088	3.19	(3.16–3.22)	–	–	–
Oligodendroglioma	3,973	1.3	43	0.27	(0.26–0.28)	3,973	0.27	(0.26–0.28)	–	–	–
Anaplastic oligodendroglioma	1,687	0.5	49	0.11	(0.11–0.12)	1,685	0.11	(0.11–0.12)	–	–	–
Oligoastrocytic tumors	3,020	1.0	42	0.21	(0.20–0.21)	3,019	0.21	(0.20–0.21)	–	–	–
Ependymal tumors	6,117	2.0	43	0.41	(0.40–0.42)	3,906	0.26	(0.26–0.27)	2,211	0.15	(0.14–0.16)
Glioma malignant, NOS	6,574	2.1	40	0.45	(0.44–0.46)	6,574	0.45	(0.44–0.46)	–	–	–
Choroid plexus tumors	772	0.2	19	0.05	(0.05–0.06)	133	0.01	(0.01–0.01)	639	0.04	(0.04–0.05)
Other neuroepithelial tumors	95	0.0	38	0.01	(0.01–0.01)	59	0.00	(0.00–0.01)	36	0.00	(0.00–0.00)
Neuronal and mixed neuronal–glial tumors	3,887	1.2	27	0.27	(0.26–0.28)	806	0.05	(0.05–0.06)	3,081	0.21	(0.21–0.22)
Tumors of the pineal region	579	0.2	34	0.04	(0.04–0.04)	324	0.02	(0.02–0.03)	255	0.02	(0.02–0.02)
Embryonal tumors	3,707	1.2	8	0.26	(0.25–0.27)	3,612	0.25	(0.24–0.26)	95	0.01	(0.01–0.01)
Tumors of Cranial and Spinal Nerves	25,942	8.3	54	1.70	(1.68–1.73)	241	0.02	(0.01–0.02)	25,701	1.69	(1.67–1.71)
Nerve sheath tumors	25,926	8.3	54	1.70	(1.68–1.72)	241	0.02	(0.01–0.02)	25,685	1.69	(1.67–1.71)
Other tumors of cranial and spinal nerves	16	0.0	58	0.00	(0.00–0.00)	–	–	–	16	0.00	(0.00–0.00)
Tumors of Meninges	114,363	36.7	65	7.49	(7.45–7.54)	2,587	0.17	(0.16–0.18)	111,776	7.32	(7.28–7.37)
Meningioma	110,359	35.5	65	7.22	(7.18–7.27)	1,878	0.12	(0.12–0.13)	108,481	7.10	(7.06–7.14)
Mesenchymal tumors	1,192	0.4	47	0.08	(0.08–0.09)	374	0.03	(0.02–0.03)	818	0.06	(0.05–0.06)
Primary melanocytic lesions	106	0.0	50	0.01	(0.01–0.01)	71	0.01	(0.00–0.01)	35	0.00	(0.00–0.00)
Other neoplasms related to the meninges	2,706	0.9	48	0.18	(0.17–0.19)	264	0.02	(0.02–0.02)	2,442	0.16	(0.16–0.17)
Lymphomas and Hemopoietic Neoplasms	6,956	2.2	64	0.46	(0.45–0.47)	6,920	0.46	(0.45–0.47)	36	0.00	(0.00–0.00)
Lymphoma	6,774	2.2	65	0.45	(0.44–0.46)	6,773	0.45	(0.44–0.46)	–	–	–
Other hemopoietic neoplasms	182	0.1	51	0.01	(0.01–0.01)	147	0.01	(0.01–0.01)	35	0.00	(0.00–0.00)
Germ Cell Tumors and Cysts	1,418	0.5	17	0.10	(0.09–0.10)	947	0.07	(0.06–0.07)	471	0.03	(0.03–0.04)
Germ cell tumors, cysts and heterotopias	1,418	0.5	17	0.10	(0.09–0.10)	947	0.07	(0.06–0.07)	471	0.03	(0.03–0.04)
Tumors of Sellar Region	46,562	15.0	50	3.12	(3.09–3.15)	140	0.01	(0.01–0.01)	46,422	3.11	(3.08–3.14)
Tumors of the pituitary	43,882	14.1	51	2.94	(2.91–2.97)	133	0.01	(0.01–0.01)	43,749	2.93	(2.90–2.96)
Craniopharyngioma	2,680	0.9	41	0.18	(0.18–0.19)	–	–	–	2,673	0.18	(0.18–0.19)
Unclassified Tumors	16,898	5.4	65	1.12	(1.10–1.13)	6,442	0.42	(0.41–0.43)	10,456	0.70	(0.68–0.71)
Hemangioma	3,240	1.0	49	0.22	(0.21–0.23)	20	0.00	(0.00–0.00)	3,220	0.22	(0.21–0.22)
Neoplasm, unspecified	13,566	4.4	71	0.89	(0.88–0.91)	6,402	0.42	(0.41–0.43)	7,164	0.47	(0.46–0.49)
All other	92	0.0	61	0.01	(0.01–0.01)	20	0.00	(0.00–0.00)	72	0.01	(0.00–0.01)
Total^‡	311,202	100.0	59	20.59	(20.52–20.66)	109,695	7.28	(7.24–7.33)	201,507	13.31	(13.25–13.37)

Histology			Age at Diagnosis								Age at Diagnosis
	0-14		0-19		20-34		35-44		45-54		55-64		65-74		75-84		85 +
	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI
Tumors of Neuroepithelial Tissue	3.77	(3.70-3.84)	3.51	(3.45-3.57)	3.26	(3.20-3.33)	4.49	(4.40-4.59)	6.98	(6.87-7.10)	11.92	(11.75-12.09)	17.57	(17.30-17.84)	19.37	(19.03-19.71)	12.14	(11.72-12.57)
Pilocytic astrocytoma	0.87	(0.84-0.91)	0.80	(0.78-0.83)	0.24	(0.23-0.26)	0.12	(0.10-0.13)	0.09	(0.08-0.10)	0.08	(0.07-0.10)	0.07	(0.06-0.09)	0.07	(0.05-0.09)	–	–
Diffuse astrocytoma	0.27	(0.25-0.29)	0.27	(0.25-0.28)	0.49	(0.46-0.51)	0.64	(0.61-0.67)	0.64	(0.61-0.68)	0.84	(0.80-0.89)	1.14	(1.07-1.21)	1.28	(1.19-1.37)	0.71	(0.61-0.82)
Anaplastic astrocytoma	0.08	(0.07-0.09)	0.08	(0.07-0.09)	0.26	(0.24-0.28)	0.35	(0.33-0.38)	0.43	(0.41-0.46)	0.67	(0.63-0.71)	0.92	(0.86-0.98)	0.96	(0.88-1.04)	0.40	(0.33-0.48)
Unique astrocytoma variants	0.10	(0.09-0.11)	0.11	(0.10-0.12)	0.06	(0.05-0.07)	0.04	(0.03-0.05)	0.04	(0.03-0.05)	0.04	(0.03-0.05)	0.04	(0.03-0.06)	0.06	(0.05-0.09)	–	–
Glioblastoma	0.13	(0.12-0.15)	0.14	(0.13-0.15)	0.39	(0.37-0.41)	1.21	(1.16-1.25)	3.66	(3.58-3.74)	8.16	(8.02-8.30)	13.21	(12.98-13.45)	14.64	(14.34-14.94)	8.96	(8.59-9.33)
Oligodendroglioma	0.04	(0.04-0.05)	0.06	(0.05-0.07)	0.32	(0.30-0.34)	0.49	(0.46-0.52)	0.42	(0.39-0.45)	0.33	(0.30-0.36)	0.25	(0.22-0.28)	0.18	(0.15-0.22)	0.07	(0.05-0.12)
Anaplastic oligodendroglioma	0.01	(0.01-0.01)	0.01	(0.01-0.02)	0.09	(0.08-0.10)	0.17	(0.15-0.19)	0.18	(0.17-0.20)	0.22	(0.20-0.25)	0.19	(0.17-0.22)	0.14	(0.11-0.17)	–	–
Oligoastrocytic tumors	0.03	(0.02-0.04)	0.03	(0.03-0.04)	0.28	(0.26-0.30)	0.35	(0.32-0.37)	0.28	(0.26-0.31)	0.26	(0.24-0.29)	0.23	(0.20-0.26)	0.16	(0.13-0.19)	–	–
Ependymal tumors	0.28	(0.26-0.30)	0.27	(0.26-0.29)	0.36	(0.33-0.38)	0.49	(0.46-0.52)	0.58	(0.55-0.62)	0.59	(0.55-0.62)	0.55	(0.50-0.59)	0.37	(0.32-0.42)	0.11	(0.07-0.16)
Glioma malignant, NOS	0.70	(0.67-0.73)	0.58	(0.56-0.61)	0.23	(0.22-0.25)	0.24	(0.22-0.26)	0.28	(0.25-0.30)	0.39	(0.36-0.42)	0.68	(0.63-0.73)	1.22	(1.14-1.31)	1.55	(1.40-1.71)
Choroid plexus tumors	0.11	(0.10-0.12)	0.10	(0.09-0.11)	0.04	(0.03-0.05)	0.04	(0.03-0.05)	0.03	(0.03-0.04)	0.04	(0.03-0.05)	0.03	(0.02-0.04)	0.04	(0.03-0.06)	–	–
Other neuroepithelial tumors	0.01	(0.01-0.01)	0.01	(0.01-0.01)	0.01	(0.00-0.01)	–	–	0.01	(0.01-0.01)	–	–	–	–	–	–	–	–
Neuronal and mixed neuronal-glial tumors	0.33	(0.31-0.35)	0.36	(0.34-0.38)	0.29	(0.27-0.30)	0.23	(0.21-0.25)	0.21	(0.19-0.23)	0.22	(0.19-0.24)	0.19	(0.16-0.22)	0.18	(0.15-0.22)	0.08	(0.05-0.12)
Tumors of the pineal region	0.04	(0.03-0.05)	0.04	(0.04-0.05)	0.04	(0.04-0.05)	0.04	(0.03-0.05)	0.05	(0.04-0.06)	0.04	(0.03-0.05)	0.04	(0.02-0.05)	–	–	–	–
Embryonal tumors	0.78	(0.75-0.81)	0.65	(0.62-0.67)	0.18	(0.17-0.20)	0.10	(0.09-0.12)	0.08	(0.07-0.09)	0.05	(0.04-0.07)	0.04	(0.03-0.06)	0.05	(0.03-0.07)	–	–
Tumors of Cranial and Spinal Nerves	0.24	(0.23-0.26)	0.27	(0.26-0.29)	0.80	(0.76-0.83)	1.75	(1.69-1.81)	2.90	(2.83-2.97)	3.90	(3.81-4.00)	4.21	(4.08-4.34)	3.26	(3.12-3.40)	1.71	(1.55-1.87)
Nerve sheath tumors	0.24	(0.23-0.26)	0.27	(0.26-0.29)	0.79	(0.76-0.83)	1.75	(1.69-1.81)	2.90	(2.83-2.97)	3.90	(3.81-4.00)	4.20	(4.07-4.34)	3.26	(3.12-3.40)	1.70	(1.55-1.87)
Other tumors of cranial and spinal nerves	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Tumors of Meninges	0.15	(0.14-0.17)	0.21	(0.20-0.23)	1.51	(1.47-1.56)	4.64	(4.55-4.74)	8.79	(8.66-8.92)	14.47	(14.28-14.66)	24.74	(24.42-25.06)	35.47	(35.01-35.93)	45.11	(44.29-45.94)
Meningioma	0.09	(0.08-0.10)	0.14	(0.12-0.15)	1.27	(1.23-1.31)	4.31	(4.22-4.40)	8.41	(8.29-8.53)	14.02	(13.83-14.20)	24.26	(23.95-24.58)	35.06	(34.60-35.52)	44.90	(44.08-45.73)
Mesenchymal tumors	0.04	(0.03-0.05)	0.04	(0.03-0.04)	0.06	(0.06-0.07)	0.10	(0.08-0.11)	0.10	(0.09-0.11)	0.14	(0.12-0.15)	0.14	(0.12-0.17)	0.12	(0.09-0.15)	0.08	(0.05-0.13)
Primary melanocytic lesions	–	–	0.01	(0.00-0.01)	–	–	–	–	0.01	(0.01-0.02)	0.01	(0.01-0.02)	0.02	(0.01-0.03)	–	–	–	–
Other neoplasms related to the meninges	0.02	(0.01-0.02)	0.03	(0.03-0.04)	0.17	(0.16-0.19)	0.23	(0.21-0.25)	0.27	(0.25-0.29)	0.31	(0.28-0.34)	0.32	(0.29-0.36)	0.27	(0.23-0.32)	0.13	(0.09-0.18)
Lymphomas and Hemopoietic Neoplasms	0.02	(0.01-0.02)	0.02	(0.02-0.03)	0.12	(0.11-0.14)	0.28	(0.26-0.30)	0.48	(0.45-0.51)	0.92	(0.88-0.97)	1.86	(1.77-1.95)	2.23	(2.11-2.35)	1.06	(0.94-1.20)
Lymphoma	0.01	(0.01-0.02)	0.02	(0.01-0.02)	0.12	(0.11-0.13)	0.27	(0.25-0.29)	0.47	(0.44-0.50)	0.90	(0.85-0.95)	1.83	(1.74-1.92)	2.21	(2.09-2.33)	1.05	(0.93-1.18)
Other hemopoietic neoplasms	0.01	(0.00-0.01)	0.01	(0.01-0.01)	0.01	(0.00-0.01)	0.01	(0.01-0.02)	0.01	(0.01-0.02)	0.02	(0.02-0.03)	0.03	(0.02-0.04)	–	–	–	–
Germ Cell Tumors and Cysts	0.18	(0.16-0.19)	0.20	(0.19-0.22)	0.11	(0.10-0.12)	0.05	(0.04-0.06)	0.03	(0.02-0.04)	0.03	(0.02-0.03)	0.03	(0.02-0.05)	0.03	(0.02-0.04)	–	–
Germ cell tumors, cysts and heterotopias	0.18	(0.16-0.19)	0.20	(0.19-0.22)	0.11	(0.10-0.12)	0.05	(0.04-0.06)	0.03	(0.02-0.04)	0.03	(0.02-0.03)	0.03	(0.02-0.05)	0.03	(0.02-0.04)	–	–
Tumors of Sellar Region	0.39	(0.37-0.41)	0.66	(0.63-0.68)	2.68	(2.62-2.74)	3.65	(3.56-3.73)	4.17	(4.08-4.25)	5.04	(4.93-5.15)	6.78	(6.61-6.95)	6.36	(6.16-6.56)	4.14	(3.90-4.40)
Tumors of the pituitary	0.18	(0.17-0.20)	0.47	(0.45-0.49)	2.56	(2.50-2.62)	3.48	(3.40-3.56)	3.96	(3.88-4.05)	4.80	(4.69-4.91)	6.53	(6.37-6.70)	6.17	(5.98-6.37)	4.07	(3.82-4.32)
Craniopharyngioma	0.21	(0.19-0.22)	0.19	(0.18-0.21)	0.13	(0.11-0.14)	0.17	(0.15-0.19)	0.21	(0.19-0.23)	0.24	(0.22-0.26)	0.25	(0.22-0.28)	0.18	(0.15-0.22)	0.08	(0.05-0.12)
Unclassified Tumors	0.22	(0.20-0.24)	0.25	(0.24-0.27)	0.50	(0.47-0.52)	0.72	(0.69-0.76)	0.96	(0.92-1.00)	1.44	(1.38-1.50)	2.54	(2.44-2.64)	5.16	(4.99-5.34)	11.09	(10.69-11.51)
Hemangioma	0.05	(0.05-0.06)	0.07	(0.06-0.08)	0.18	(0.16-0.19)	0.26	(0.24-0.28)	0.31	(0.29-0.34)	0.35	(0.32-0.38)	0.39	(0.36-0.44)	0.36	(0.31-0.41)	0.25	(0.20-0.32)
Neoplasm, unspecified	0.16	(0.15-0.18)	0.18	(0.17-0.19)	0.32	(0.30-0.34)	0.46	(0.43-0.49)	0.64	(0.61-0.68)	1.07	(1.02-1.12)	2.13	(2.04-2.22)	4.78	(4.61-4.95)	10.81	(10.41-11.22)
All other	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total^‡	4.97	(4.89-5.05)	5.13	(5.06-5.20)	8.98	(8.88-9.09)	15.58	(15.41-15.75)	24.31	(24.10-24.52)	37.72	(37.41-38.02)	57.72	(57.24-58.21)	71.86	(71.21-72.52)	75.27	(74.21-76.34)

	Age At Diagnosis								Age at Diagnosis
	0-4		5-9		10-14		15-19		0-19^‡		0-14^‡
	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI
Tumors of Neuroepithelial Tissue	4.50	(4.37-4.63)	3.68	(3.56-3.81)	3.17	(3.06-3.28)	2.74	(2.64-2.84)	3.51	(3.45-3.57)	3.77	(3.70-3.84)
Pilocytic astrocytoma	0.87	(0.82-0.93)	0.89	(0.83-0.95)	0.86	(0.80-0.92)	0.59	(0.55-0.64)	0.80	(0.78-0.83)	0.87	(0.84-0.91)
Diffuse astrocytoma	0.33	(0.29-0.37)	0.22	(0.19-0.25)	0.26	(0.23-0.30)	0.26	(0.23-0.29)	0.27	(0.25-0.28)	0.27	(0.25-0.29)
Anaplastic astrocytoma	0.05	(0.04-0.07)	0.08	(0.07-0.10)	0.09	(0.07-0.11)	0.09	(0.08-0.11)	0.08	(0.07-0.09)	0.08	(0.07-0.09)
Unique astrocytoma variants	0.06	(0.05-0.08)	0.10	(0.08-0.12)	0.14	(0.11-0.16)	0.13	(0.11-0.16)	0.11	(0.10-0.12)	0.10	(0.09-0.11)
Glioblastoma	0.09	(0.07-0.11)	0.14	(0.12-0.17)	0.16	(0.14-0.19)	0.17	(0.14-0.19)	0.14	(0.13-0.15)	0.13	(0.12-0.15)
Oligodendroglioma	0.03	(0.02-0.04)	0.04	(0.03-0.05)	0.06	(0.04-0.08)	0.11	(0.09-0.13)	0.06	(0.05-0.07)	0.04	(0.04-0.05)
Anaplastic oligodendroglioma	–	–	–	–	–	–	0.02	(0.02-0.04)	0.01	(0.01-0.02)	0.01	(0.01-0.01)
Oligoastrocytic tumors	0.03	(0.02-0.04)	0.03	(0.02-0.04)	0.03	(0.02-0.05)	0.05	(0.04-0.07)	0.03	(0.03-0.04)	0.03	(0.02-0.04)
Ependymal tumors	0.40	(0.36-0.44)	0.23	(0.20-0.26)	0.21	(0.19-0.24)	0.26	(0.23-0.30)	0.27	(0.26-0.29)	0.28	(0.26-0.30)
Glioma malignant, NOS	0.86	(0.81-0.92)	0.81	(0.75-0.87)	0.43	(0.39-0.47)	0.24	(0.22-0.28)	0.58	(0.56-0.61)	0.70	(0.67-0.73)
Choroid plexus tumors	0.26	(0.23-0.29)	0.04	(0.03-0.06)	0.04	(0.03-0.05)	0.05	(0.04-0.06)	0.10	(0.09-0.11)	0.11	(0.10-0.12)
Other neuroepithelial tumors	–	–	–	–	–	–	–	–	0.01	(0.01-0.01)	0.01	(0.01-0.01)
Neuronal and mixed neuronal-glial tumors	0.24	(0.21-0.28)	0.30	(0.27-0.34)	0.43	(0.39-0.48)	0.46	(0.42-0.51)	0.36	(0.34-0.38)	0.33	(0.31-0.35)
Tumors of the pineal region	0.05	(0.04-0.07)	0.04	(0.03-0.05)	0.03	(0.02-0.05)	0.04	(0.03-0.05)	0.04	(0.04-0.05)	0.04	(0.03-0.05)
Embryonal tumors	1.21	(1.15-1.28)	0.76	(0.70-0.81)	0.39	(0.35-0.43)	0.25	(0.22-0.28)	0.65	(0.62-0.67)	0.78	(0.75-0.81)
Tumors of Cranial and Spinal Nerves	0.27	(0.24-0.30)	0.21	(0.18-0.24)	0.26	(0.22-0.29)	0.35	(0.32-0.39)	0.27	(0.26-0.29)	0.24	(0.23-0.26)
Nerve sheath tumors	0.27	(0.24-0.30)	0.21	(0.18-0.24)	0.26	(0.22-0.29)	0.35	(0.32-0.39)	0.27	(0.26-0.29)	0.24	(0.23-0.26)
Other tumors of cranial and spinal nerves	–	–	–	–	–	–	–	–	–	–	–	–
Tumors of Meninges	0.14	(0.12-0.16)	0.10	(0.08-0.12)	0.21	(0.18-0.24)	0.39	(0.36-0.43)	0.21	(0.20-0.23)	0.15	(0.14-0.17)
Meningioma	0.07	(0.05-0.09)	0.06	(0.05-0.08)	0.14	(0.12-0.17)	0.26	(0.23-0.30)	0.14	(0.12-0.15)	0.09	(0.08-0.10)
Mesenchymal tumors	0.06	(0.04-0.07)	0.03	(0.02-0.04)	0.03	(0.02-0.04)	0.03	(0.02-0.05)	0.04	(0.03-0.04)	0.04	(0.03-0.05)
Primary melanocytic lesions	–	–	–	–	–	–	–	–	0.01	(0.00-0.01)	–	–
Other neoplasms related to the meninges	–	–	–	–	0.03	(0.02-0.05)	0.09	(0.07-0.11)	0.03	(0.03-0.04)	0.02	(0.01-0.02)
Lymphomas and Hemopoietic Neoplasms	–	–	0.02	(0.01-0.03)	0.02	(0.01-0.03)	0.03	(0.02-0.05)	0.02	(0.02-0.03)	0.02	(0.01-0.02)
Lymphoma	–	–	–	–	–	–	0.02	(0.02-0.04)	0.02	(0.01-0.02)	0.01	(0.01-0.02)
Other hemopoietic neoplasms	–	–	–	–	–	–	–	–	0.01	(0.01-0.01)	0.01	(0.00-0.01)
Germ Cell Tumors and Cysts	0.13	(0.11-0.15)	0.14	(0.11-0.16)	0.27	(0.23-0.30)	0.29	(0.26-0.32)	0.20	(0.19-0.22)	0.18	(0.16-0.19)
Germ cell tumors, cysts and heterotopias	0.13	(0.11-0.15)	0.14	(0.11-0.16)	0.27	(0.23-0.30)	0.29	(0.26-0.32)	0.20	(0.19-0.22)	0.18	(0.16-0.19)
Tumors of Sellar Region	0.17	(0.15-0.20)	0.37	(0.33-0.41)	0.61	(0.57-0.67)	1.46	(1.39-1.53)	0.66	(0.63-0.68)	0.39	(0.37-0.41)
Tumors of the pituitary	0.03	(0.02-0.05)	0.11	(0.09-0.13)	0.40	(0.36-0.44)	1.31	(1.24-1.38)	0.47	(0.45-0.49)	0.18	(0.17-0.20)
Craniopharyngioma	0.14	(0.12-0.16)	0.26	(0.23-0.29)	0.22	(0.19-0.25)	0.15	(0.13-0.18)	0.19	(0.18-0.21)	0.21	(0.19-0.22)
Unclassified Tumors	0.22	(0.19-0.25)	0.18	(0.15-0.21)	0.26	(0.22-0.29)	0.36	(0.33-0.40)	0.25	(0.24-0.27)	0.22	(0.20-0.24)
Hemangioma	0.05	(0.04-0.06)	0.04	(0.03-0.05)	0.08	(0.06-0.09)	0.13	(0.11-0.15)	0.07	(0.06-0.08)	0.05	(0.05-0.06)
Neoplasm, unspecified	0.17	(0.15-0.20)	0.14	(0.12-0.17)	0.18	(0.15-0.21)	0.23	(0.20-0.26)	0.18	(0.17-0.19)	0.16	(0.15-0.18)
All other	–	–	–	–	–	–	–	–	–	–	–	–
Total^§	5.43	(5.29-5.58)	4.70	(4.56-4.84)	4.79	(4.65-4.93)	5.63	(5.49-5.77)	5.13	(5.06-5.20)	4.97	(4.89-5.05)

ICCC Category	0-19^‡ years			0-14^‡ years		< 1 year		1-4 years		5-9 years		10-14 years		15-19 years
	Count	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI
II Lymphomas and reticuloendothelial neoplasms	69	0.02	(0.01-0.02)	0.01	(0.01-0.02)	–	–	–	–	0.02	(0.01-0.03)	0.02	(0.01-0.03)	0.03	(0.02-0.04)
III CNS and misc intracranial and intraspinal neoplasms	17,654	4.38	(4.31-4.44)	4.32	(4.25-4.40)	4.53	(4.24-4.83)	4.82	(4.67-4.97)	4.21	(4.08-4.34)	4.03	(3.91-4.16)	4.53	(4.41-4.67)
III(a) Ependymomas and choroid plexus tumor	1,506	0.37	(0.35-0.39)	0.39	(0.37-0.41)	0.93	(0.80-1.07)	0.59	(0.54-0.64)	0.27	(0.24-0.31)	0.25	(0.22-0.29)	0.31	(0.28-0.35)
III(b) Astrocytomas	6,277	1.56	(1.52-1.60)	1.66	(1.61-1.70)	1.25	(1.10-1.41)	1.92	(1.83-2.02)	1.61	(1.53-1.69)	1.58	(1.50-1.66)	1.27	(1.21-1.34)
III(c) Intracranial and intraspinal embryonal tumors	2,408	0.60	(0.57-0.62)	0.72	(0.69-0.75)	1.19	(1.04-1.35)	1.04	(0.97-1.11)	0.73	(0.67-0.78)	0.37	(0.34-0.41)	0.23	(0.21-0.27)
III(d) Other gliomas	2,135	0.53	(0.51-0.56)	0.58	(0.55-0.61)	0.26	(0.20-0.34)	0.61	(0.56-0.67)	0.70	(0.65-0.76)	0.49	(0.44-0.53)	0.40	(0.37-0.44)
III(e) Other specified intracranial and intraspinal neoplasms	4,602	1.14	(1.11-1.17)	0.82	(0.79-0.86)	0.61	(0.51-0.73)	0.51	(0.47-0.57)	0.76	(0.70-0.81)	1.17	(1.10-1.24)	2.08	(2.00-2.17)
III(f) Unspecified intracranial and intraspinal neoplasms	726	0.18	(0.17-0.19)	0.16	(0.15-0.18)	0.29	(0.22-0.38)	0.14	(0.12-0.17)	0.14	(0.12-0.16)	0.18	(0.15-0.21)	0.23	(0.20-0.26)
IV Neuroblastoma and other peripheral nervous cell tumors	206	0.05	(0.04-0.06)	0.06	(0.05-0.07)	0.28	(0.21-0.37)	0.09	(0.07-0.11)	0.03	(0.02-0.04)	0.02	(0.02-0.04)	0.03	(0.02-0.04)
IX Soft tissue and other extraosseous sarcomas	1,667	0.41	(0.39-0.43)	0.35	(0.33-0.37)	0.56	(0.46-0.67)	0.33	(0.29-0.37)	0.28	(0.25-0.32)	0.39	(0.35-0.43)	0.60	(0.55-0.65)
X(a) Intracranial & intraspinal germ cell tumors	823	0.20	(0.19-0.22)	0.18	(0.16-0.19)	0.38	(0.30-0.48)	0.06	(0.05-0.08)	0.14	(0.11-0.16)	0.27	(0.23-0.30)	0.29	(0.26-0.32)
All other categories	290	0.07	(0.06-0.08)	0.04	(0.04-0.05)	–	–	0.04	(0.02-0.05)	0.03	(0.02-0.05)	0.06	(0.05-0.08)	0.15	(0.13-0.18)
Total^§	20,709	5.13	(5.06-5.20)	4.97	(4.89-5.05)	5.82	(5.49-6.16)	5.33	(5.18-5.50)	4.70	(4.56-4.84)	4.79	(4.65-4.93)	5.63	(5.49-5.77)

Histology	ICD-O-3^‡ Histology Code
Tumors of Neuroepithelial Tissue
Pilocytic astrocytoma	9421/1 [Included with malignant tumors]
Unique astrocytoma variants	9384/1
Ependymal tumors	9383/1; 9394/1
Choroid plexus	9390/0,1
Other neuroepithelial tumors	9363/0; 9444/1
Neuronal and mixed neuronalglial tumors	8680/0,1; 8681/1; 8690/1; 8693/1; 9412/1; 9413/0; 9442/1;
	9492/0 (excluding site C75.1); 9493/0; 9505/1; 9506/1
Tumors of the pineal region	9360/1; 9361/1
Embryonal tumors	9490/0
Tumors of Cranial and Spinal Nerves
Nerve sheath tumors	9540/0,1; 9541/0, 9550/0; 9560/0,1; 9570/0; 9571/0
Other tumors of cranial and spinal nerves	9562/0
Tumors of Meninges
Meningioma	9530/0,1; 9531/0; 9532/0; 9533/0; 9534/0; 9537/0; 9538/1; 9539/1
Mesenchymal tumors	8324/0; 8800/0; 8810/0; 8815/0; 8824/0,1; 8830/0,1; 8831/0; 8835/1; 8836/1;
	8850/0,1; 8851/0; 8852/0, 8854/0; 8857/0; 8861/0; 8870/0; 8880/0, 8890/0,1; 8897/1;
	8900/0; 8920/1; 8935/0,1; 8990/0,1; 9040/0; 9136/1, 9150/0,1; 9170/0; 9180/0; 9210/0; 9241/0; 9373/0
Primary melanocytic lesions	8728/0,1; 8770/0; 8771/0
Other neoplasms related to the meninges	9161/1; 9220/0,1; 9535/0
Lymphomas and Hemopoietic Neoplasms
Other hemopoietic neoplasms	9740/1; 9751/1; 9752/1; 9753/1; 9766/1; 9970/1
Germ Cell Tumors and Cysts
Germ cell tumors, cysts and heterotopias	8440/0; 9080/0,1; 9084/0
Tumors of Sellar Region
Tumors of the pituitary	8040/0,1; 8140/0,1; 8146/0; 8260/0; 8270/0; 8271/0; 8272/0;
	8280/0; 8281/0; 8290/0; 8300/0; 8310/0; 8323/0; 9492/0 (site C75.1 only); 9582/0
Craniopharyngioma	9350/1; 9351/1; 9352/1
Unclassified Tumors
Hemangioma	9120/0; 9121/0; 9122/0; 9123/0; 9125/0; 9130/0,1; 9131/0; 9133/1
Neoplasm, unspecified	8000/0,1; 8001/0,1; 8005/0; 8010/0
All other	8452/1; 8711/0; 8713/0; 8811/0; 8840/0; 9173/0; 9580/0

State	Total			Males			Females
	N	Rate	95% CI	N	Rate	95% CI	N	Rate	95% CI
Alabama	1,148	4.58	(4.31–4.85)	626	5.55	(5.12–6.01)	522	3.76	(3.45–4.11)
Alaska	111	4.20	(3.39–5.14)	65	4.96	(3.67–6.52)	46	3.56	(2.55–4.81)
Arizona	1,336	4.11	(3.90–4.34)	743	4.87	(4.52–5.23)	593	3.46	(3.19–3.76)
Arkansas	775	4.95	(4.60–5.31)	417	5.90	(5.34–6.50)	358	4.15	(3.73–4.62)
California	7,457	4.31	(4.21–4.41)	4,225	5.32	(5.16–5.49)	3,232	3.46	(3.34–3.58)
Colorado	1,016	4.40	(4.13–4.68)	586	5.45	(5.00–5.92)	430	3.51	(3.18–3.86)
Connecticut	809	4.22	(3.93–4.52)	436	5.07	(4.60–5.58)	373	3.52	(3.16–3.90)
Delaware	212	4.54	(3.95–5.20)	119	5.75	(4.75–6.89)	93	3.60	(2.90–4.43)
Washington DC	101	3.47	(2.82–4.23)	57	4.44	(3.33–5.78)	44	2.67	(1.93–3.60)
Florida	4,385	3.95	(3.83–4.07)	2,455	4.81	(4.62–5.01)	1,930	3.19	(3.05–3.34)
Georgia	1,671	3.87	(3.68–4.06)	913	4.67	(4.36–5.00)	758	3.22	(2.99–3.46)
Hawaii	171	2.39	(2.04–2.78)	98	2.92	(2.36–3.57)	73	1.95	(1.52–2.47)
Idaho	379	5.14	(4.63–5.69)	202	5.63	(4.87–6.48)	177	4.62	(3.96–5.36)
Illinois	2,523	3.89	(3.74–4.05)	1,387	4.74	(4.49–5.00)	1,136	3.19	(3.01–3.39)
Indiana	1,526	4.62	(4.39–4.86)	819	5.46	(5.08–5.85)	707	3.93	(3.64–4.23)
Iowa	918	5.53	(5.17–5.90)	526	6.95	(6.36–7.57)	392	4.33	(3.90–4.80)
Kansas	735	5.07	(4.70–5.45)	422	6.39	(5.79–7.03)	313	3.93	(3.50–4.40)
Kentucky	1,021	4.49	(4.21–4.77)	565	5.46	(5.01–5.94)	456	3.66	(3.33–4.02)
Louisiana	1,007	4.53	(4.25–4.82)	565	5.63	(5.17–6.13)	442	3.61	(3.28–3.96)
Maine	403	5.12	(4.63–5.66)	233	6.47	(5.65–7.38)	170	4.00	(3.41–4.67)
Maryland	1,094	3.78	(3.56–4.02)	590	4.57	(4.20–4.97)	504	3.15	(2.88–3.44)
Massachusetts	1,517	4.25	(4.03–4.47)	847	5.38	(5.02–5.76)	670	3.35	(3.10–3.62)
Michigan	2,602	4.86	(4.67–5.05)	1,458	5.99	(5.68–6.31)	1,144	3.95	(3.72–4.19)
Minnesota	1,165	4.33	(4.09–4.59)	644	5.18	(4.78–5.60)	521	3.60	(3.30–3.93)
Mississippi	693	4.67	(4.32–5.03)	362	5.50	(4.93–6.10)	331	3.99	(3.57–4.45)
Missouri	1,468	4.58	(4.35–4.82)	793	5.45	(5.07–5.84)	675	3.86	(3.57–4.17)
Montana	248	4.53	(3.97–5.14)	147	5.53	(4.66–6.52)	101	3.63	(2.94–4.43)
Nebraska	475	5.13	(4.67–5.61)	256	6.01	(5.29–6.80)	219	4.30	(3.74–4.93)
Nevada	517	4.10	(3.75–4.48)	318	5.21	(4.64–5.84)	199	3.09	(2.67–3.55)
New Hampshire	338	4.76	(4.26–5.30)	202	6.11	(5.28–7.03)	136	3.62	(3.03–4.30)
New Jersey	1,720	3.69	(3.51–3.87)	970	4.65	(4.36–4.96)	750	2.90	(2.70–3.12)
New Mexico	375	3.66	(3.30–4.05)	216	4.48	(3.89–5.13)	159	2.95	(2.50–3.45)
New York	3,861	3.70	(3.58–3.82)	2,193	4.74	(4.54–4.95)	1,668	2.87	(2.74–3.02)
North Carolina	1,893	4.05	(3.87–4.24)	1,044	5.01	(4.71–5.33)	849	3.28	(3.06–3.51)
North Dakota	174	5.02	(4.29–5.83)	89	5.63	(4.51–6.95)	85	4.42	(3.51–5.50)
Ohio	2,794	4.44	(4.27–4.61)	1,527	5.36	(5.09–5.64)	1,267	3.66	(3.46–3.88)
Oklahoma	897	4.68	(4.38–5.00)	491	5.60	(5.11–6.13)	406	3.85	(3.47–4.25)
Oregon	1,056	5.19	(4.88–5.52)	624	6.56	(6.05–7.10)	432	4.05	(3.67–4.46)
Pennsylvania	3,008	4.10	(3.95–4.25)	1,623	4.95	(4.71–5.20)	1,385	3.41	(3.23–3.60)

STATE	2012 Estimated New Cases			2013 Estimated New Cases
	Total	Malignant	Non-Malignant	Total	Malignant	Non-Malignant
Alabama	1,070	360	710	1,090	370	720
Alaska	130	50	90	140	50	90
Arizona	1,530	560	970	1,590	580	1,010
Arkansas	670	240	430	680	240	440
California	7,560	2,670	4,890	7,700	2,710	4,980
Colorado	1,090	400	690	1,120	410	710
Connecticut	810	290	520	820	290	530
Delaware	210	70	140	220	80	140
District of Columbia	130	–	90	130	–	90
Florida	4,780	1,680	3,100	4,890	1,710	3,180
Georgia	2,090	700	1,380	2,150	720	1,420
Hawaii	260	80	180	260	80	180
Idaho	350	130	220	360	130	220
Illinois	2,770	970	1,800	2,800	980	1,820
Indiana	1,430	520	910	1,450	520	930
Iowa	700	260	440	710	260	450
Kansas	620	230	390	630	230	400
Kentucky	990	360	630	1,000	360	640
Louisiana	940	320	630	950	320	630
Maine	340	120	210	340	130	220
Maryland	1,260	410	850	1,280	420	860
Massachusetts	1,510	540	970	1,520	540	980
Michigan	2,280	800	1,480	2,310	810	1,490
Minnesota	1,180	430	750	1,200	440	760
Mississippi	640	210	430	640	210	430
Missouri	1,370	490	880	1,390	500	900
Montana	240	90	150	240	90	150
Nebraska	400	150	250	400	150	260
Nevada	600	220	390	630	230	400
New Hampshire	320	120	200	330	120	210
New Jersey	1,950	680	1,280	1,970	680	1,290
New Mexico	450	160	290	460	170	290
New York	4,380	1,500	2,890	4,430	1,510	2,920
North Carolina	2,130	730	1,400	2,190	750	1,430
North Dakota	150	50	90	150	50	90
Ohio	2,660	940	1,710	2,690	950	1,730
Oklahoma	800	290	520	810	290	520
Oregon	900	330	570	920	340	590
Pennsylvania	3,020	1,070	1,950	3,050	1,080	1,970

			1-Yr		2-Yr		5-Yr		10-Yr
ICD-O-3 CODE	SITE^‡	N	%	95% CI	%	95% CI	%	95% CI	%	95% CI
C71.1	Frontal lobe of the brain	13,584	60.1	(59.3-61.0)	45.4	(44.5-46.3)	34.4	(33.5-35.3)	26.1	(25.1-27.2)
C71.2	Temporal lobe of the brain	9,759	55.0	(54.0-56.0)	33.9	(32.9-34.9)	22.3	(21.4-23.3)	17.1	(16.0-18.2)
C71.3	Parietal lobe of the brain	6,655	47.5	(46.3-48.8)	28.7	(27.6-29.9)	18.8	(17.7-19.9)	12.9	(11.7-14.2)
C71.4	Occipital lobe of the brain	1,657	50.0	(47.5-52.5)	30.6	(28.3-33.0)	20.9	(18.7-23.2)	16.8	(14.3-19.4)
C71.0	Cerebrum	2,979	48.2	(46.4-50.1)	34.0	(32.2-35.8)	25.8	(24.1-27.6)	22.5	(20.6-24.4)
C71.5	Ventricle	1,069	75.4	(72.6-77.9)	67.6	(64.6-70.5)	61.9	(58.6-65.0)	57.1	(53.2-60.8)
C71.6	Cerebellum	3,380	84.6	(83.3-85.8)	78.4	(76.9-79.8)	70.8	(69.0-72.5)	65.9	(63.8-67.9)
C71.7	Brain stem	2,706	69.3	(67.5-71.1)	56.3	(54.3-58.2)	47.8	(45.7-49.9)	42.7	(40.3-45.1)
C71.8-C71.9	Other brain	13,529	42.4	(41.5-43.2)	29.8	(29.0-30.6)	21.2	(20.4-21.9)	16.5	(15.7-17.4)
C72.0-C72.1	Spinal cord and cauda equina	2,025	89.0	(87.5-90.4)	84.6	(82.8-86.2)	79.6	(77.4-81.6)	75.4	(72.3-78.2)
C72.2-C72.5	Cranial nerves	609	95.8	(93.8-97.2)	94.3	(91.9-96.0)	91.4	(88.4-93.6)	90.7	(87.2-93.4)
C72.8-C72.9	Other nervous system	581	60.0	(55.8-64.0)	50.1	(45.7-54.4)	42.5	(37.8-47.1)	36.7	(31.0-42.5)
C70.0-C70.9	Meninges (cerebral and spinal)	1,164	82.0	(79.5-84.2)	74.9	(72.0-77.6)	64.2	(60.7-67.5)	55.3	(50.5-59.9)
C75.1-C75.2	Pituitary and craniopharyngeal duct	242	84.1	(78.5-88.3)	80.6	(74.5-85.4)	71.5	(64.3-77.5)	62.9	(53.8-70.7)
C75.3	Pineal	615	87.8	(84.8-90.2)	80.4	(76.8-83.5)	73.3	(69.1-77.0)	67.1	(61.5-72.0)
C30.0 (9522-9523)	Olfactory tumors of the nasal cavity	430	90.2	(86.7-92.8)	82.7	(78.4-86.3)	75.3	(70.0-79.8)	60.8	(53.4-67.4)
All Codes	All Sites	60,984	57.5	(57.1-57.9)	43.2	(42.8-43.6)	33.8	(33.3-34.2)	28.0	(27.5-28.5)

Age Group	2000 U.S.	Age Group	2000 U.S.	Age Group	2000 U.S.
0-4	18,986,520	45-49	19,805,793	Total	274,633,642
5-9	19,919,840	50-54	17,224,359
10-14	20,056,779	55-59	13,307,234
15-19	19,819,518	60-64	10,654,272
20-24	18,257,225	65-69	9,409,940
25-29	17,722,067	70-74	8,725,574
30-34	19,511,370	75-79	7,414,559
35-39	22,179,956	80-84	4,900,234
40-44	22,479,229	85 +	4,259,173

Age Group	White	Black	AIAN	API	Total
Male
0-4	8,037,698	1,622,527	159,258	566,834	10,386,317
5-9	7,793,666	1,544,900	139,946	509,083	9,987,595
10-14	7,888,319	1,627,045	139,972	479,511	10,134,847
15-19	8,338,842	1,715,900	153,160	486,529	10,694,432
20-24	8,410,996	1,576,574	151,010	519,412	10,657,993
25-29	8,228,350	1,428,057	137,050	594,488	10,387,945
30-34	7,691,310	1,233,338	117,988	633,887	9,676,522
35-39	8,218,599	1,248,410	113,550	616,955	10,197,514
40-44	8,663,105	1,268,913	113,563	545,955	10,591,536
45-49	9,048,219	1,247,998	110,007	492,833	10,899,056
50-54	8,355,171	1,071,350	94,187	426,708	9,947,415
55-59	7,320,322	847,538	76,093	355,164	8,599,117
60-64	5,772,849	579,643	54,121	257,295	6,663,908
65-69	4,288,055	419,179	37,341	191,508	4,936,083
70-74	3,336,984	321,809	25,633	140,338	3,824,763
75-79	2,737,962	230,861	17,366	98,399	3,084,587
80-84	1,963,511	144,799	10,494	64,648	2,183,452
85+	1,444,483	88,929	7,413	49,597	1,590,423
Total	117,538,441	18,217,770	1,658,152	7,029,142	144,443,505
Female
0-4	7,662,890	1,567,047	154,968	546,376	9,931,281
5-9	7,416,719	1,496,348	135,425	494,935	9,543,427
10-14	7,484,741	1,576,475	135,679	461,321	9,658,217
15-19	7,865,425	1,667,329	148,312	460,551	10,141,617
20-24	7,830,296	1,533,923	142,567	503,546	10,010,332
25-29	7,725,919	1,475,962	126,944	621,460	9,950,284
30-34	7,280,280	1,350,815	109,913	664,590	9,405,598
35-39	7,905,500	1,393,178	108,591	649,284	10,056,553
40-44	8,501,828	1,436,436	113,580	583,877	10,635,721
45-49	9,052,206	1,435,380	115,242	539,788	11,142,615
50-54	8,501,688	1,260,910	100,959	484,785	10,348,341
55-59	7,595,609	1,029,493	81,966	415,962	9,123,030
60-64	6,170,532	739,907	59,158	301,314	7,270,911
65-69	4,800,958	568,866	41,640	223,716	5,635,180
70-74	3,985,644	464,588	30,806	176,326	4,657,364
75-79	3,606,677	375,056	22,573	138,650	4,142,956
80-84	3,039,413	275,902	15,663	96,536	3,427,514
85 +	3,181,222	241,124	15,156	84,328	3,521,830
Total	119,607,548	19,888,738	1,659,141	7,447,345	148,602,772

Age Group	Hispanic	Non-Hispanic	Total
Male
0-4	2,591,526	7,794,790	10,386,317
5-9	2,206,575	7,781,020	9,987,595
10-14	1,994,101	8,140,746	10,134,847
15-19	1,937,795	8,756,636	10,694,432
20-24	2,015,006	8,642,987	10,657,993
25-29	2,191,048	8,196,897	10,387,945
30-34	2,071,604	7,604,918	9,676,522
35-39	1,872,881	8,324,633	10,197,514
40-44	1,630,191	8,961,346	10,591,536
45-49	1,339,787	9,559,269	10,899,056
50-54	1,013,168	8,934,247	9,947,415
55-59	748,483	7,850,634	8,599,117
60-64	520,940	6,142,969	6,663,908
65-69	366,071	4,570,012	4,936,083
70-74	271,035	3,553,729	3,824,763
75-79	199,994	2,884,594	3,084,587
80-84	128,533	2,054,919	2,183,452
85 +	92,899	1,497,524	1,590,423
Total	23,191,636	121,251,869	144,443,505
Female
0-4	2,485,956	7,445,325	9,931,281
5-9	2,106,961	7,436,465	9,543,427
10-14	1,900,666	7,757,551	9,658,217
15-19	1,799,832	8,341,785	10,141,617
20-24	1,732,051	8,278,281	10,010,332
25-29	1,778,951	8,171,333	9,950,284
30-34	1,724,996	7,680,602	9,405,598
35-39	1,621,039	8,435,514	10,056,553
40-44	1,464,772	9,170,949	10,635,721
45-49	1,265,587	9,877,029	11,142,615
50-54	1,007,437	9,340,904	10,348,341
55-59	786,589	8,336,441	9,123,030
60-64	581,503	6,689,407	7,270,911
65-69	434,780	5,200,400	5,635,180
70-74	344,316	4,313,047	4,657,364
75-79	272,247	3,870,710	4,142,956
80-84	191,020	3,236,494	3,427,514
85 +	176,572	3,345,258	3,521,830
Total	21,675,276	126,927,496	148,602,772

PERMALINK

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005–2009

Therese A Dolecek

Jennifer M Propp

Nancy E Stroup

Carol Kruchko

Introduction

Background

Technical Notes

Data Collection

Definitions

Measures in Surveillance Epidemiology

Classification by Behavior and Histology

Table 1.

Table 1a.

Table 1b.

Anatomic Location of Tumor Sites

Measurement Methods

Brain Tumor Definition Differences

Estimation of Expected Numbers of Brain and CNS Tumors in 2012 and 2013

Estimation of Mortality Rates for Underlying Cause from Brain and CNS Tumors

Estimation of Survival Rates

Data Interpretation

Results

Primary Brain and CNS Tumors: Distributions and Incidence by Histology Group, Histology, Gender, Race, Hispanic Ethnicity, Age Group, Cancer Registry and Behavior

Table 2.

Table 3.

Table 4.

Table 5.

Overall Incidence Rates

Fig. 1.

Overall Incidence Rates by Year

Fig. 2.

Incidence Rates by Central Cancer Registry, Age, and Behavior

Table 6.

Primary Brain and CNS Tumors: Incidence by Site, Histology, Age, Gender, Race, and Hispanic Ethnicity

Distribution of Tumors by Site and Histology

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Incidence of Spinal Cord Tumors

Fig. 7.

Distribution of Tumors by Site and Histology in Young Adults (Ages 20-34 Years)

Fig. 8.

Incidence Rates by Site and Gender

Table 7.

Incidence Rates by Major Histology Groupings and Specific Histologies

Table 8.

Incidence Rates by Behavior and Histology

Median Age at Diagnosis

Incidence Rates by Gender and Histology

Table 9.

Fig. 9.

Incidence Rates by Race and Histology

Table 10.

Fig. 10.

Incidence Rates by Hispanic Ethnicity and Histology

Table 11.

Incidence Rates by Age and Histology

Table 12.

Fig. 11.

Fig. 12.

Childhood Primary Brain and CNS Tumors: Incidence by Site, Histology, Gender, and Age

Childhood Brain Tumors

Distribution of Tumors by Site and Histology

Fig. 13.

Fig. 14.

Childhood Incidence Rates by Histology and Gender

Table 13.

Childhood Incidence Rates by Histology and Race

Table 14.

Childhood Incidence rates by Histology and Hispanic Ethnicity

Table 15.

Childhood Incidence Rates by Age and Histology

Table 16.

Fig. 15.

Childhood Incidence Rates by Histology Defined by ICCC

Table 17.

Mortality Rates, Expected Incidence, and Survival